Chip may detect spreading cancer cells in blood
|
Tweet
|
|
Researchers have found a way to test blood for the cells that spread cancer and said they might be able to use the method to predict whose cancer will come back after treatment.
The team at Harvard Medical School and Massachusetts General Hospital used a grant from a non-profit group to develop the test, which they tried out on samples from 20 men with prostate cancer.
They found circulating tumor cells in patients with tumors that had not spread, low-grade cancers and in patients who had their prostate glands taken out three months before.
"These are patient groups in whom we would normally not expect to see circulating tumor cells, so it gives us a tremendous amount of information about their risk,” said Harvard’s Sunitha Nagrath, who led the study.
“Are these patients more prone to come back with recurring disease?” she asked a news conference at a meeting of the American Association for Cancer Research. She said her team would follow the patients to see if the tumors came back in patients who had the circulating cancer cells.
Such a test may also some day serve as a blood test for prostate cancer in addition to PSA or prostate specific antigen tests, which look for a protein made only by prostate cells and which can indicate cancer.
Nagrath said her team’s test can detect 200 circulating tumor cells from a teaspoon of blood taken from a cancer patient.
Prostate cancer is the leading cancer killer of men after lung cancer. But it is often a slow-growing disease and doctors are unsure which men have the most deadly types and which men are most likely to have their cancer spread or come back.
The researchers looked for the circulating tumor cells in the blood one day and nine days after the men had their prostates removed, and then again more than three months later.
They found cells in 42 percent of the patients, and in 64 percent of those with advanced prostate cancer.
The cells could not be found right after surgery but reappeared in some of the patients.
Nagrath said it will be important to follow the men to see how well they do and whether those with more of the circulating cells do more poorly.
She also said the test may be useful for monitoring patients on so-called targeted therapies, which affect cancer cells with certain specific genetic mutations.
“With blood tests you can sample the patients every day to see whether the genotype is changing,” she said.
The charity Stand Up To Cancer paid for the trial.
---
By Maggie Fox
WASHINGTON (Reuters)
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
- Full Story - - »»»
Child addicts at heart of Indonesia anti-smoking suit
- Full Story - - »»»
Miracle sweetener stevia may have a sour note
- Full Story - - »»»
Scientists turn skin cells into beating heart muscle
- Full Story - - »»»
Too many people get angioplasties, study suggests
- Full Story - - »»»
Viewers’ family background affects how they react to MTV shows ‘16 and Pregnant,’ ‘Teen Mom’
- Full Story - - »»»
Weight management in pregnancy with diet is beneficial and safe and can reduce complications
- Full Story - - »»»

